Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Chromocell Therapeutics Corporation

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. In our flavors and nutrition business, Chromocell works with global consumer goods companies to discover and develop flavor ingredients and natural taste enhancers. The technology is applicable to all areas of taste sensations as well as aroma and fragrance enhancer discovery.

	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
asset turnover
cash per share			0.03 -	0.01 68.21%	0.01 11.74%	0.01 68.48%	0.00 72.18%	0.02 315.09%	0.65 3,886.77%	0.42 36.29%	0.22 47.99%
company equity multiplier			1.08 -	-0.01 101.38%	-0.01 25.67%	-0.02 51.29%	-0.00 76.91%	-0.01 287.58%	3.57 23,950.89%	-14.26 499.86%	-1.50 89.49%
days of inventory outstanding
days of payables outstanding				687.85 -	1.63K 136.30%	6.38K 292.63%		161.23 -	464.37 188.01%
days of sales outstanding
dividend yield			0.00 -
ebit per revenue
ebt per ebit	1.08 -	1.13 4.40%	1.07 4.72%	1.06 1.10%	1.06 0.41%	1.23 16.07%	1.10 10.28%	1.04 5.39%	1.32 27.23%	1.00 24.20%	0.83 17.62%
effective tax rate			0.31 -	0.23 24.73%	0.95 305.43%	0.82 13.85%	0.91 11.45%	0.96 5.70%	0.75 21.40%
enterprise value multiple			-53.79 -	-40.42 24.86%	-31.02 23.24%	-36.78 18.56%	-22.34 39.26%	-7.58 66.09%	-5.18 31.67%	-3.63 29.93%	-1.40 61.53%
fixed asset turnover
free cash flow per share	-0.04 -	-0.05 13.41%	-0.06 23.88%	-0.12 86.47%	-0.03 73.99%	-0.03 11.68%	-0.04 32.86%	-0.06 36.11%	-0.35 469.01%	-0.51 48.04%	-0.03 93.99%
gross profit margin
interest coverage	-12.73 -	-7.93 37.71%	-13.72 72.99%	-16.36 19.20%	-17.60 7.58%	-4.41 74.93%	-9.94 125.25%	-24.19 143.48%	-3.08 87.28%	-159.50 5,082.20%	52.50 132.91%
inventory turnover
long term debt to capitalization
net income per ebt	1 -	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%	1 0%
net profit margin
operating cash flow per share	-0.04 -	-0.05 13.41%	-0.06 23.88%	-0.12 86.47%	-0.03 73.99%	-0.03 11.68%	-0.04 32.86%	-0.06 36.11%	-0.35 469.01%	-0.51 48.04%	-0.03 93.99%
operating profit margin
payables turnover				0.13 -	0.06 57.68%	0.01 74.53%		0.56 -	0.19 65.28%
pretax profit margin
price fair value			0.67 -	-7.47 1,213.78%	-6.29 15.78%	-5.65 10.20%	-4.69 17.00%	-4.38 6.63%	12.20 378.57%	-39.54 424.23%	-2.88 92.71%
receivables turnover
return on assets			-0.01 -	-13.43 107,166.31%	-19.88 48.07%	-11.64 41.46%	-62.39 435.98%	-41.90 32.84%	-0.64 98.48%	-0.68 7.06%	-0.79 16.38%
return on capital employed			-0.01 -	0.19 1,596.19%	0.21 10.52%	0.16 23.69%	0.22 37.96%	0.60 175.12%	-1.71 384.33%	9.67 664.78%	1.43 85.15%
return on equity			-0.01 -	0.20 1,579.81%	0.22 10.07%	0.19 11.43%	0.24 23.78%	0.63 160.30%	-2.27 461.75%	9.71 528.10%	1.19 87.77%
total debt to capitalization			0.01 -	-0.17 1,888.39%	-0.20 18.23%	-0.25 24.39%	-0.25 1.53%	-0.25 3.82%		1.13 -

COM:CHROMOCELL

Chromocell

Last Close

0.62

21/11 20:47

Market Cap

3.80M

Beta: -

Volume Today

52.69K

Avg: -

Preview